A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving ‘complete remission’ in gastro‐oesophageal reflux disease
Summary Background and Aim The outcome of gastro‐oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing and symptom relief separately. Both terms together, indicating complete remission, are intuitively a more realistic clinical endpoint but are...
Saved in:
Published in | Alimentary pharmacology & therapeutics Vol. 25; no. 12; pp. 1461 - 1469 |
---|---|
Main Authors | , , , |
Format | Journal Article |
Language | English |
Published |
Oxford, UK
Blackwell Publishing Ltd
15.06.2007
Blackwell |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Summary
Background and Aim The outcome of gastro‐oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing and symptom relief separately. Both terms together, indicating complete remission, are intuitively a more realistic clinical endpoint but are assessed less often.
Aim To explore this concept, we formally compared the efficacy of the proton pump inhibitors (PPIs) pantoprazole and esomeprazole using rates of complete remission judged against rates of healing and symptom relief separately.
Methods Five hundred and eighty‐two patients with erosive gastro‐oesophageal reflux disease were randomized to treatment for 4, 8, or 12 weeks with either pantoprazole or esomeprazole 40 mg daily. Symptom relief was assessed with the validated ReQuest™‐GI subscale.
Results Approximately 75% of patients were free of symptoms or had no oesophageal lesions after 4 weeks’ treatment, rising to about 93% and 96%, respectively, at 12 weeks. Complete remission rates were, however, lower at these time points; approximately 60% and about 90%, respectively. Both PPIs had similar efficacy.
Conclusions Endoscopically confirmed healing and symptom relief assessed separately over‐estimated the benefits of both drugs. In contrast, complete remission indicates that patients may be treated inadequately when given the standard 4‐ to 8‐week treatment. We suggest that complete remission is a more reliable and clinically relevant endpoint of treatment. |
---|---|
AbstractList | Summary
Background and Aim The outcome of gastro‐oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing and symptom relief separately. Both terms together, indicating complete remission, are intuitively a more realistic clinical endpoint but are assessed less often.
Aim To explore this concept, we formally compared the efficacy of the proton pump inhibitors (PPIs) pantoprazole and esomeprazole using rates of complete remission judged against rates of healing and symptom relief separately.
Methods Five hundred and eighty‐two patients with erosive gastro‐oesophageal reflux disease were randomized to treatment for 4, 8, or 12 weeks with either pantoprazole or esomeprazole 40 mg daily. Symptom relief was assessed with the validated ReQuest™‐GI subscale.
Results Approximately 75% of patients were free of symptoms or had no oesophageal lesions after 4 weeks’ treatment, rising to about 93% and 96%, respectively, at 12 weeks. Complete remission rates were, however, lower at these time points; approximately 60% and about 90%, respectively. Both PPIs had similar efficacy.
Conclusions Endoscopically confirmed healing and symptom relief assessed separately over‐estimated the benefits of both drugs. In contrast, complete remission indicates that patients may be treated inadequately when given the standard 4‐ to 8‐week treatment. We suggest that complete remission is a more reliable and clinically relevant endpoint of treatment. The outcome of gastro-oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing and symptom relief separately. Both terms together, indicating complete remission, are intuitively a more realistic clinical endpoint but are assessed less often. To explore this concept, we formally compared the efficacy of the proton pump inhibitors (PPIs) pantoprazole and esomeprazole using rates of complete remission judged against rates of healing and symptom relief separately. Five hundred and eighty-two patients with erosive gastro-oesophageal reflux disease were randomized to treatment for 4, 8, or 12 weeks with either pantoprazole or esomeprazole 40 mg daily. Symptom relief was assessed with the validated ReQuesttrade mark-GI subscale. Approximately 75% of patients were free of symptoms or had no oesophageal lesions after 4 weeks' treatment, rising to about 93% and 96%, respectively, at 12 weeks. Complete remission rates were, however, lower at these time points; approximately 60% and about 90%, respectively. Both PPIs had similar efficacy. Endoscopically confirmed healing and symptom relief assessed separately over-estimated the benefits of both drugs. In contrast, complete remission indicates that patients may be treated inadequately when given the standard 4- to 8-week treatment. We suggest that complete remission is a more reliable and clinically relevant endpoint of treatment. BACKGROUND AND AIMThe outcome of gastro-oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing and symptom relief separately. Both terms together, indicating complete remission, are intuitively a more realistic clinical endpoint but are assessed less often.AIMTo explore this concept, we formally compared the efficacy of the proton pump inhibitors (PPIs) pantoprazole and esomeprazole using rates of complete remission judged against rates of healing and symptom relief separately.METHODSFive hundred and eighty-two patients with erosive gastro-oesophageal reflux disease were randomized to treatment for 4, 8, or 12 weeks with either pantoprazole or esomeprazole 40 mg daily. Symptom relief was assessed with the validated ReQuesttrade mark-GI subscale.RESULTSApproximately 75% of patients were free of symptoms or had no oesophageal lesions after 4 weeks' treatment, rising to about 93% and 96%, respectively, at 12 weeks. Complete remission rates were, however, lower at these time points; approximately 60% and about 90%, respectively. Both PPIs had similar efficacy.CONCLUSIONSEndoscopically confirmed healing and symptom relief assessed separately over-estimated the benefits of both drugs. In contrast, complete remission indicates that patients may be treated inadequately when given the standard 4- to 8-week treatment. We suggest that complete remission is a more reliable and clinically relevant endpoint of treatment. Summary Background and Aim The outcome of gastro‐oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing and symptom relief separately. Both terms together, indicating complete remission, are intuitively a more realistic clinical endpoint but are assessed less often. Aim To explore this concept, we formally compared the efficacy of the proton pump inhibitors (PPIs) pantoprazole and esomeprazole using rates of complete remission judged against rates of healing and symptom relief separately. Methods Five hundred and eighty‐two patients with erosive gastro‐oesophageal reflux disease were randomized to treatment for 4, 8, or 12 weeks with either pantoprazole or esomeprazole 40 mg daily. Symptom relief was assessed with the validated ReQuest™‐GI subscale. Results Approximately 75% of patients were free of symptoms or had no oesophageal lesions after 4 weeks’ treatment, rising to about 93% and 96%, respectively, at 12 weeks. Complete remission rates were, however, lower at these time points; approximately 60% and about 90%, respectively. Both PPIs had similar efficacy. Conclusions Endoscopically confirmed healing and symptom relief assessed separately over‐estimated the benefits of both drugs. In contrast, complete remission indicates that patients may be treated inadequately when given the standard 4‐ to 8‐week treatment. We suggest that complete remission is a more reliable and clinically relevant endpoint of treatment. |
Author | PFAFFENBERGER, B. RIDDERMANN, T. ACHIM, A. BARDHAN, K. D. |
Author_xml | – sequence: 1 givenname: K. D. surname: BARDHAN fullname: BARDHAN, K. D. – sequence: 2 givenname: A. surname: ACHIM fullname: ACHIM, A. – sequence: 3 givenname: T. surname: RIDDERMANN fullname: RIDDERMANN, T. – sequence: 4 givenname: B. surname: PFAFFENBERGER fullname: PFAFFENBERGER, B. |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18796318$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/17539986$$D View this record in MEDLINE/PubMed |
BookMark | eNqNkc1uEzEUhS1URNPCKyBvYDeDZzz-mQWLqOJPqgSLsrYcz53EkWMP9gRSVnkElq3E0-VJ8DSBbvHCvrr-7rlHOhfozAcPCOGKlFU-b9ZlRTkrakJ5WRMiSkIpFeXuCZr9-zhDM1LztqhlRc_RRUprQggXpH6GzivBaNtKPkO_59g4663RDo_R5tuEzaCj9Us8aD-GIeqfwQHWvsOQwgb-NsaAYTe4EHO5gjzmDQwjDj3WZmXh-6Rw2N9Ncg5GwBE2NiUb_GF_j63HS53GGA77XyHLDiu9hLw8Qu-2O9zZBDrBc_S01y7Bi9N7ib6-f3dz9bG4_vzh09X8ujBNI0QhF6zpG06E1Lyr60VL2o62xkBPOe86xusGMikJaygTueItbSkjzDRS1pWkl-j1UXeI4dsW0qiyVQPOaQ9hm5QgjDFCRQblETQxpJTNqiHajY63qiJqSkat1RSAmgJQUzLqIRm1y6MvTzu2iw10j4OnKDLw6gTolNPoo_bGpkdOipbTB7Nvj9wP6-D2vw2o-ZebqaJ_AJfWsMI |
CitedBy_id | crossref_primary_10_1007_s00464_009_0384_8 crossref_primary_10_1177_17562848241251567 crossref_primary_10_4137_CMT_S4500 crossref_primary_10_1097_MEG_0b013e3282f246b2 crossref_primary_10_2165_00003495_200868110_00009 crossref_primary_10_2165_00044011_200727100_00001 crossref_primary_10_1097_MD_0000000000008120 crossref_primary_10_1097_MD_0000000000031807 crossref_primary_10_1016_j_dld_2007_09_008 crossref_primary_10_1016_j_rgmx_2012_10_002 crossref_primary_10_1097_MCG_0b013e31816207cb crossref_primary_10_1097_MEG_0b013e3282f1cc39 crossref_primary_10_1016_j_bpg_2010_09_004 crossref_primary_10_1111_apt_12540 crossref_primary_10_2165_11590270_000000000_00000 crossref_primary_10_1111_jgh_14664 crossref_primary_10_1517_17425250903124363 crossref_primary_10_1097_MEG_0b013e328358bf74 crossref_primary_10_1586_17474124_1_2_197 crossref_primary_10_2165_1153121_S0_000000000_00000 crossref_primary_10_1097_MEG_0b013e3282f1a2b5 |
Cites_doi | 10.1023/B:DDAS.0000007857.15694.15 10.1016/j.dld.2003.09.003 10.1111/j.1572-0241.2003.07531.x 10.1159/000085564 10.1136/gut.45.2.172 10.1136/gut.31.9.968 10.1159/000079708 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I 10.1159/000079707 10.1136/gut.44.2008.S1 10.1111/j.1365-2036.2004.02194.x |
ContentType | Journal Article |
Copyright | 2007 INIST-CNRS |
Copyright_xml | – notice: 2007 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
DOI | 10.1111/j.1365-2036.2007.03337.x |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic CrossRef |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1365-2036 |
EndPage | 1469 |
ExternalDocumentID | 10_1111_j_1365_2036_2007_03337_x 17539986 18796318 APT3337 |
Genre | article Multicenter Study Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- .3N .GA .GJ .Y3 05W 0R~ 10A 1OB 1OC 23M 24P 31~ 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5VS 66C 6J9 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAZKR ABCQN ABCUV ABDBF ABEML ABJNI ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AIACR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BAWUL BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF D-6 D-7 D-E D-F DC6 DCZOG DIK DPXWK DR2 DRFUL DRMAN DRSTM DTERQ E3Z EAD EAP EAS EBC EBD EBS EBX EJD EMB EMK EMOBN EST ESX EX3 F00 F01 F04 F5P FEDTE FIJ FUBAC FZ0 G-S G.N GODZA GX1 H.X HF~ HGLYW HVGLF HZI HZ~ IHE IPNFZ IX1 J0M K48 KBYEO LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK0 MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D P6G PALCI Q.N Q11 QB0 Q~Q R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ SV3 TEORI TR2 TUS UB1 V8K V9Y W8V W99 WBKPD WH7 WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YOC ZZTAW ~IA ~WT AAJUZ AAVGM ABCVL ABHUG ABPTK ACXME ADAWD ADDAD AFVGU AGJLS IQODW ZA5 CGR CUY CVF ECM EIF NPM AAYXX CITATION 7X8 |
ID | FETCH-LOGICAL-c4477-8b54f46078a6d22b909d39ccef366dd5624ec448054357c4469393505c4882183 |
IEDL.DBID | DR2 |
ISSN | 0269-2813 |
IngestDate | Fri Aug 16 01:20:59 EDT 2024 Fri Aug 23 03:20:18 EDT 2024 Thu May 23 23:11:13 EDT 2024 Sun Oct 22 16:03:56 EDT 2023 Sat Aug 24 00:54:38 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 12 |
Keywords | Human Gastroesophageal reflux Pantoprazole Enzyme Esophageal disease H Enzyme inhibitor Antiulcer agent K Proton pump inhibitor Benzimidazole derivatives Antisecretory agent Esomeprazole Digestive diseases exchanging ATPase Hydrolases Clinical trial Remission |
Language | English |
License | CC BY 4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c4477-8b54f46078a6d22b909d39ccef366dd5624ec448054357c4469393505c4882183 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-News-2 ObjectType-Feature-3 content type line 23 |
OpenAccessLink | https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1365-2036.2007.03337.x |
PMID | 17539986 |
PQID | 70555037 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_70555037 crossref_primary_10_1111_j_1365_2036_2007_03337_x pubmed_primary_17539986 pascalfrancis_primary_18796318 wiley_primary_10_1111_j_1365_2036_2007_03337_x_APT3337 |
PublicationCentury | 2000 |
PublicationDate | 2007-06-15 |
PublicationDateYYYYMMDD | 2007-06-15 |
PublicationDate_xml | – month: 06 year: 2007 text: 2007-06-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | Oxford, UK |
PublicationPlace_xml | – name: Oxford, UK – name: Oxford – name: England |
PublicationTitle | Alimentary pharmacology & therapeutics |
PublicationTitleAlternate | Aliment Pharmacol Ther |
PublicationYear | 2007 |
Publisher | Blackwell Publishing Ltd Blackwell |
Publisher_xml | – name: Blackwell Publishing Ltd – name: Blackwell |
References | 1990; 31 2004; 20 1998; 17 2006; 42 2000 2004; 69 2003; 8 2003; 35 1999; 45 1999; 44 2003; 48 2005; 71 1989; 13 2003; 98 Zeitoun P (e_1_2_6_14_2) 1989; 13 Monnikes H (e_1_2_6_17_2) 2006; 42 e_1_2_6_8_2 e_1_2_6_7_2 e_1_2_6_9_2 e_1_2_6_4_2 e_1_2_6_3_2 e_1_2_6_6_2 e_1_2_6_5_2 e_1_2_6_12_2 e_1_2_6_13_2 e_1_2_6_10_2 e_1_2_6_11_2 Bate CM (e_1_2_6_16_2) 1990; 31 Locke GR (e_1_2_6_2_2) 2003; 8 e_1_2_6_15_2 |
References_xml | – volume: 69 start-page: 238 year: 2004 end-page: 44 article-title: Evaluation of GERD symptoms during therapy Part II. Psychometric evaluation and validation of the new questionnaire ReQuest in erosive GERD publication-title: Digestion – volume: 48 start-page: 2237 year: 2003 end-page: 41 article-title: Clinical symptoms in endoscopic reflux esophagitis: evaluation in 8031 adult subjects publication-title: Dig Dis Sci – volume: 35 start-page: 843 year: 2003 end-page: 8 article-title: Unsolved problems in the management of patients with gastro‐oesophageal reflux disease publication-title: Dig Liver Dis – volume: 71 start-page: 145 year: 2005 end-page: 51 article-title: Determination of ReQuest‐based symptom thresholds to define symptom relief in GERD clinical studies publication-title: Digestion – volume: 17 start-page: 873 year: 1998 end-page: 90 article-title: Interval estimation for the difference between independent proportions: comparison of eleven methods publication-title: Stat Med – year: 2000 – volume: 13 start-page: 457 year: 1989 end-page: 62 article-title: Omeprazole (20 mg daily) compared to ranitidine (150 mg twice daily) in the treatment of esophagitis caused by reflux results of a double‐blind randomized multicenter trial in France and Belgium publication-title: Gastroenterol Clin Biol – volume: 20 start-page: 891 year: 2004 end-page: 8 article-title: International validation of ReQuest in patients with endoscopy‐negative gastro‐oesophageal reflux disease publication-title: Aliment Pharmacol Ther – volume: 31 start-page: 968 year: 1990 end-page: 72 article-title: Comparison of omeprazole and cimetidine in reflux oesophagitis: symptomatic, endoscopic, and histological evaluations publication-title: Gut – volume: 31 start-page: A1190 year: 1990 article-title: Omeprazole 20 mg o.m. vs. ranitidine 150 mg b.d. in reflux oesophagitis: omeprazole 40 mg o.m – a strategy fortreatment failures publication-title: Gut – volume: 8 start-page: 61 year: 2003 end-page: 70 article-title: Can symptoms predict endoscopic findings in GERD? publication-title: Gastrointest Endosc – volume: 98 start-page: 1487 year: 2003 end-page: 93 article-title: Nighttime heartburn is an under‐appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association publication-title: Am J Gastroenterol – volume: 45 start-page: 172 year: 1999 end-page: 80 article-title: Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification publication-title: Gut – volume: 42 start-page: 9 year: 2006 end-page: 14 article-title: The complete remission concept publication-title: Drugs Today (Barc) – volume: 44 start-page: S1 year: 1999 end-page: 16 article-title: on behalf of the Genval Workshop Group. An evidence‐based appraisal of reflux disease management – the Genval Workshop Report publication-title: Gut – volume: 69 start-page: 229 year: 2004 end-page: 37 article-title: Evaluation of GERD symptoms during therapy Part I. Development of the new GERD questionnaire ReQuest publication-title: Digestion – ident: e_1_2_6_5_2 doi: 10.1023/B:DDAS.0000007857.15694.15 – volume: 42 start-page: 9 year: 2006 ident: e_1_2_6_17_2 article-title: The complete remission concept publication-title: Drugs Today (Barc) contributor: fullname: Monnikes H – ident: e_1_2_6_4_2 doi: 10.1016/j.dld.2003.09.003 – ident: e_1_2_6_7_2 doi: 10.1111/j.1572-0241.2003.07531.x – ident: e_1_2_6_11_2 doi: 10.1159/000085564 – volume: 8 start-page: 61 year: 2003 ident: e_1_2_6_2_2 article-title: Can symptoms predict endoscopic findings in GERD? publication-title: Gastrointest Endosc contributor: fullname: Locke GR – volume: 31 start-page: A1190 year: 1990 ident: e_1_2_6_16_2 article-title: Omeprazole 20 mg o.m. vs. ranitidine 150 mg b.d. in reflux oesophagitis: omeprazole 40 mg o.m – a strategy fortreatment failures publication-title: Gut contributor: fullname: Bate CM – ident: e_1_2_6_6_2 doi: 10.1136/gut.45.2.172 – ident: e_1_2_6_15_2 doi: 10.1136/gut.31.9.968 – ident: e_1_2_6_9_2 doi: 10.1159/000079708 – ident: e_1_2_6_13_2 doi: 10.1002/(SICI)1097-0258(19980430)17:8<873::AID-SIM779>3.0.CO;2-I – ident: e_1_2_6_12_2 – ident: e_1_2_6_8_2 doi: 10.1159/000079707 – volume: 13 start-page: 457 year: 1989 ident: e_1_2_6_14_2 article-title: Omeprazole (20 mg daily) compared to ranitidine (150 mg twice daily) in the treatment of esophagitis caused by reflux results of a double‐blind randomized multicenter trial in France and Belgium publication-title: Gastroenterol Clin Biol contributor: fullname: Zeitoun P – ident: e_1_2_6_3_2 doi: 10.1136/gut.44.2008.S1 – ident: e_1_2_6_10_2 doi: 10.1111/j.1365-2036.2004.02194.x |
SSID | ssj0006702 |
Score | 2.0241895 |
Snippet | Summary
Background and Aim The outcome of gastro‐oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing... The outcome of gastro-oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing and symptom relief... Summary Background and Aim The outcome of gastro‐oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing... BACKGROUND AND AIMThe outcome of gastro-oesophageal reflux disease treatment is traditionally assessed by measuring endoscopically confirmed healing and... |
SourceID | proquest crossref pubmed pascalfrancis wiley |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 1461 |
SubjectTerms | 2-Pyridinylmethylsulfinylbenzimidazoles - therapeutic use Adolescent Adult Aged Anti-Ulcer Agents - therapeutic use Biological and medical sciences Digestive system Double-Blind Method Esomeprazole - therapeutic use Esophagus Female Gastroenterology. Liver. Pancreas. Abdomen Gastroesophageal Reflux - drug therapy Humans Male Medical sciences Middle Aged Other diseases. Semiology Pharmacology. Drug treatments Remission Induction - methods Secondary Prevention Treatment Outcome Wound Healing - drug effects |
Title | A clinical trial comparing pantoprazole and esomeprazole to explore the concept of achieving ‘complete remission’ in gastro‐oesophageal reflux disease |
URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1365-2036.2007.03337.x https://www.ncbi.nlm.nih.gov/pubmed/17539986 https://search.proquest.com/docview/70555037 |
Volume | 25 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlh1IofbdxH6kOvXrxQ5as41IaQiEhlARyM7I0bktSe1l7IeS0P6HHFvrr9pd0Rra7ccihlN6EsWxrPDP6JH0zw9g7HVU2QjcXJk7JUEjaaLI2CUUsVOYqcAnQQvHwSB6cio9n2dnAf6JYmD4_xJ8NN7IM76_JwE3ZTo3cM7TQBQ-ZCNM0VTPCk5RXj_DRp20mKak8_RBXHPhZeZxOST23PmgyU91fmBaFVvXVLm6Do1N066en_YfsfBxYz0o5n626cmavbuR8_D8jf8QeDCiWz3u1e8zuQP2E3T0czumfsl9zPoZccl8XhPdcd5wn-YLKFi-W5qq5AG5qx6FtvsF4oWs4eFogNr8AdvNRlbypOLE-gbY_-Gb9wzPhEe_zJdWrox2_zfon_1rzz6btls1m_b0BKtCA3hJfjrK9WF3y4TDqGTvd_3Dy_iAc6kCEVgiFk2iZiUpIBDNGuiQpdaRdqq2FKpXSOURwAvDOHNFnmilsSU0Bx1Fm0TsRBHzOduqmhl3GjYzB4KqrtBpxYIVgSQundWkzkwOiz4DF4z8vFn26j-LaMgnFXpDYqXinKrzYi8uA7U2UY9sxV-je4jxgb0dtKVAmdCJjamhWbUGpjLIoVQF70SvRtq-ilMG5DJj0qvDXX1PMj0-o9fJfO75i90ZOZJy9ZjvdcgVvEHh15Z43qd93fSL4 |
link.rule.ids | 315,786,790,1382,27957,27958,46329,46753 |
linkProvider | Wiley-Blackwell |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQIgHSijdseOz6wDVVHn7ExwqxKrBdIdSV9mY5jgOIklRtKq321J_AESR-XX8JM05CCdoDQtysqE6Tycz4m_HnGUJeqKi0Ebi5MCmkCJnARJO1SchiJnlRuiJxGChOT8XkjL055-ddOyA8C9PWh_iVcEPL8P4aDRwT0kMr9xQt8MFdKcI0TeUIAOV1sH7u46v3u1pSQnoCIsQc8GBZnA5pPVfeabBW7S_MCsRWtv0urgKkQ3zrF6jjO2Tev1rLS_k8Wjf5yF7-UfXxP737XXK7A7J03GrePXLNVffJjWm3Vf-A_BjT_tQl9a1BaEt3h6WSLrBz8WJpLuu5o6YqqFvVX1x_oamp88xAGH50MM0frKR1SZH46TADQrebb54MD5CfLrFlHSb9tpvv9FNFP5hVs6y3m6-1wx4N4DDhz0G48_UF7fajHpKz41ezl5OwawURWsYkrKM5ZyUTgGeMKJIkV5EqUmWtK1MhigJAHHPwywwAaMoljITCM8cRt-CgEAU-IntVXbkDQo2InYHAK7cKoGAJeEmxQqnccpM5AKABifuPrhdtxQ_9W6QEYtcoduzfKbUXu74IyOFAO3YTMwkeLs4CctSriwaZ4KaMqVy9XmmsZsSjVAbkcatFu7kSqwZnIiDC68JfP40ev5vh6Mm_TjwiNyez6Yk-eX369im51VMkY_6M7DXLtXsOOKzJD719_QStyCca |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlhVAofT_cR6JDr178kCXruDRd0kdCKAnkJmRJbkpS2-x6IeS0P6HHFvrr9pd0Rra7dcmhlN6EsWxrPDP6JH0zQ8grGZUmAjcXJlbwkHHcaDImCVnMRGZLZxOHC8WDQ75_wt6dZqc9_wljYbr8EL823NAyvL9GA29sOTZyz9ACF9xnIkzTVEwAT95kPE1Qw_c-blJJceH5h7DkgO_K43TM6rn2SaOp6najFyC1sit3cR0eHcNbPz_N7pLzYWQdLeV8smyLibn6I-nj_xn6PXKnh7F02undfXLDVQ_I9kF_UP-Q_JjSIeaS-sIgtCO7w0RJG6xb3Mz1VX3hqK4sdYv6ixsutDV1nhcIzTMH3XxYJa1LirRPh_sfdL365qnwAPjpHAvW4ZbfevWdfq7oJ71o5_V69bV2WKEB3CW8HGR7sbyk_WnUI3Iye3P8ej_sC0GEhjEBs2iRsZJxQDOa2yQpZCRtKo1xZcq5tQDhmIM7c4CfaSagxSVGHEeZAfeEGPAx2arqyj0lVPPYaVh2FUYCECwBLUlmpSxMpnMH8DMg8fDPVdPl-1C_rZNA7ArFjtU7hfJiV5cB2Rkpx6ZjLsC_xXlAdgdtUSATPJLRlauXC4W5jLIoFQF50inRpq_AnME5Dwj3qvDXX6OmR8fYevavHXfJ9tHeTH14e_j-Obk18CPj7AXZaudL9xJAWFvseOv6CRX5Jck |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+clinical+trial+comparing+pantoprazole+and+esomeprazole+to+explore+the+concept+of+achieving+%27complete+remission%27+in+gastro-oesophageal+reflux+disease&rft.jtitle=Alimentary+pharmacology+%26+therapeutics&rft.au=BARDHAN%2C+K.+D&rft.au=ACHIM%2C+A&rft.au=RIDDERMANN%2C+T&rft.au=PFAFFENBERGER%2C+B&rft.date=2007-06-15&rft.pub=Blackwell&rft.issn=0269-2813&rft.eissn=1365-2036&rft.volume=25&rft.issue=12&rft.spage=1461&rft.epage=1469&rft_id=info:doi/10.1111%2Fj.1365-2036.2007.03337.x&rft.externalDBID=n%2Fa&rft.externalDocID=18796318 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0269-2813&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0269-2813&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0269-2813&client=summon |